Improvement of Metabolic Syndrome Following Intragastric Balloon: 1 Year Follow-up Analysis
Purchase on Springer.com
$39.95 / €34.95 / £29.95*
Rent the article at a discountRent now
* Final gross prices may vary according to local VAT.
This study aimed to assess the impact of intragastric balloon (IGB)-induced body weight loss on metabolic syndrome in obese patients and evaluate what happens during 1-year follow-up.
To this end, data were collected on 143 obese patients (body mass index (BMI) 36.2 ± 5.7 kg/m²) who underwent IGB insertion between January 2000 and December 2005. Outcomes were recorded at BioEnterics Intragastric Balloon removal time (t 0) and at 6-month (t 6) and 12-month (t 12) follow-up.
Significant BMI, excess body weight loss percentage, and body weight loss percentage (BWL%) were observed at t 0 (29.6 ± 4.6 kg/m²; 29.3 ± 4.8%; 14.1 ± 5.7%), followed by partial weight regain at t 12 (32.4 ± 4.3 kg/m²; 26.1 ± 4.9%; 11.2 ± 4.6%). Incidence of metabolic syndrome dropped from 34.8% (pre-IGB value) to 14.5% (t 0) and 11.6% (t 12). Likewise, type 2 diabetes mellitus (DM), hypertriglyceridemia, hypercholesterolemia, and blood hypertension (BH) incidence decreased from 32.6%, 37.7%, 33.4%, and 44.9% (pre-IGB values) to 20.9%, 14.5%, 16.7%, and 30.4% at t 0 and 21.3%, 17.4%, 18.9%, and 34.8% at t 12. HbA1c blood concentration shifted from an initial value of 7.5 ± 2.1% to 5.7 ± 1.9% (t 0), 5.6 ± 0.7% (t 6), and 5.5 ± 0.9% (t 12). Patients suffering from DM or BH stopped or diminished relative drug consumption at t 12. Negligible modifications were reported as regards HDL cholesterol and hyperuricemia.
Weight regain is commonly observed during long-term follow-up after IGB removal. Nevertheless, the maintenance of at least 10% of the BWL%, as reported at 1-year follow-up, is associated with an improvement in metabolic syndrome.
- Loffredo A, Cappuccio M, De Luca M, et al. Three years experience with the new intragastric balloon, and a preoperative test for success with restrictive surgery. Obes Surg. 2001;11:330–3. CrossRef
- Roman S, Napoleon B, Mion F, et al. Intragastric balloon for “non-morbid” obesity: a retrospective evaluation of tolerance and efficacy. Obes Surg. 2004;14:539–44. CrossRef
- Doldi SB, Micheletto G, Perrini MN, et al. Treatment of morbid obesity with intragastric balloon in association with diet. Obes Surg. 2002;12:583–92. CrossRef
- De Waele B, Reynaert H, Urbain D, et al. Intragastric balloons for preoperative weight reduction. Obes Surg. 2000;10:58–60. CrossRef
- Wahlen CH, Bastens B, Herve J, et al. The BioEnterics Intragastric Balloon (BIB): how to use it. Obes Surg. 2001;11:524–7. CrossRef
- Spyropoulos C, Katsakoulis E, Mead N, et al. Intragastric balloon for high-risk super-obese patients: a prospective analysis of efficacy. Surg Obes Relat Dis. 2007;3:78–83. CrossRef
- Sallet JA, Marchesini JB, Pavia DS, et al. Brazilian multi center study of intragastric balloon. Obes Surg. 2004;14:991–8. CrossRef
- Imaz I, Martinez-Cervell C, Garcia-Alvarez EE, et al. Safety and effectiveness of the intragastric balloon for obesity. A meta-analysis. Obes Surg. 2008;18:841–6. CrossRef
- Mittempergher F, Di Betta E, Pata G, et al. The obstructive sleep apnea in bariatric surgery. Ann Ital Chir. 2008;79:165–70.
- Alberti KG, Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med. 1998;15:539–53. CrossRef
- Strazzullo P, Barbato A, Siani A, et al. Diagnostic criteria for metabolic syndrome: a comparative analysis in an unselected sample of adult male population. Metabolism. 2008;57:355–61. CrossRef
- Pischon T, Boeing H, Hoffmann K, et al. General and abdominal adiposity and risk of death in Europe. N Engl J Med. 2008;359:2105–20. CrossRef
- Ammar KA, Redfield MM, Mahoney DW, et al. Central obesity: association with left ventricular dysfunction and mortality in the community. Am Heart J. 2008;156:975–81. CrossRef
- Shimabukuro M. Cardiac adiposity and global cardiometabolic risk: new concept and clinical intervention. Circ J. 2008;73:27–34. CrossRef
- Artham SM, Lavie CJ, Patel HM. Impact of obesity on the risk of heart failure and its prognosis. J Cardiometab Syndr. 2008;3:155–61. CrossRef
- Franz MJ, VanWormer JJ, Crain AL, et al. Weight-loss outcomes: a systematic review and meta-analysis of weight-loss clinical trials with a minimum 1-year follow-up. J Am Diet Assoc. 2007;107:1755–67. CrossRef
- Avenell A, Brown TJ, McGee MA, et al. What interventions should we add to weight reducing diets in adults with obesity? A systematic review of randomized controlled trials of adding drug therapy, exercise, behaviour therapy or combinations of these interventions. J Hum Nutr Diet. 2004;17:293–316. CrossRef
- Curioni CC, Lourenço PM. Long-term weight loss after diet and exercise: a systematic review. Int J Obes (Lond). 2005;29:1168–74. CrossRef
- Herve J, Wahlen H, Schaeken A, et al. What becomes of patients one year after the intragastric balloon has been removed? Obes Surg. 2005;15:864–70. CrossRef
- Angrisani L, Lorenzo M, Borrelli V, et al. Is bariatric surgery necessary after intragastric balloon treatment? Obes Surg. 2006;16:1135–7. CrossRef
- Mathus-Vliegen EM, Tytgat GN. Intragastric balloon for treatment-resistant obesity: safety, tolerance, and efficacy of 1-year balloon treatment followed by a 1-year balloon free follow-up. Gastrointest Endosc. 2005;61:19–27. CrossRef
- Genco A, Bruni T, Doldi SB, et al. BioEnterics intragastric Balloon: the Italian Experience with 2.515 patients. Obes Surg. 2005;15:1161–4. CrossRef
- Mui WL, Ng EK, Tsung BY et al. Impact on obesity-related illnesses and quality of life following intragastric balloon. Obes Surg. 2008; (in press).
- Ricci G, Bersani G, Rossi A, et al. Bariatric therapy with intragastric balloon improves liver dysfunction and insulin resistance in obese patients. Obes Surg. 2008;18:1438–42. CrossRef
- Deitel M. How much weight loss is sufficient to overcome major co-morbidities? Obes Surg. 2001;11:659. CrossRef
- Improvement of Metabolic Syndrome Following Intragastric Balloon: 1 Year Follow-up Analysis
Volume 19, Issue 8 , pp 1084-1088
- Cover Date
- Print ISSN
- Online ISSN
- Additional Links
- Intragastric balloon
- Metabolic syndrome
- Industry Sectors
- Author Affiliations
- 1. Department of Medical and Surgical Sciences, General Surgery, University of Brescia, Ple Spedali Civili 1, 25123, Brescia, Italy
- 2. Department of Medical and Surgical Sciences, Surgical Endoscopy, University of Brescia, Brescia, Italy
- 3. Department of Experimental and Applied Medicine, Institute of Hygiene, Epidemiology and Public Health, University of Brescia, Brescia, Italy